ReviewUrologie (Heidelberg, Germany)2026
[Pharmacotherapy of benign prostatic syndrome : Medications, innovations and future prospects].
Review in Urologie (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lower urinary tract symptoms (LUTS) affect the majority of men over 60 years old in Germany to varying degrees. These symptoms include issues with bladder storage and bladder emptying. The most common cause of such disorders by far is prostate enlargement (benign prostatic hyperplasia, BPH), which leads to urethral narrowing (benign prostatic obstruction, BPO). Due to the aging population, the prevalence of BPH is steadily increasing and a good understanding of individualized patient treatment is of major importance. Treatment options range from watchful waiting and behavioral therapy to phytotherapy and pharmacotherapy up to surgical procedures. While the range of surgical and interventional therapeutic options is rapidly expanding, innovations in conservative treatment procedures have lagged behind in recent years; however, new drugs and combination treatment with existing medications offer promising possibilities to improve the quality of life and slow progression of the disease in patients.
Indexed as
Identifiers
41879994What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.